Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BLU-222

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Blueprint Medicines, UT MD Anderson Cancer Center

Drug class:

CDK2 inhibitor

Related drugs:

CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2	BLU-222 Sensitive: C2 – Inclusion Criteria BLU-222 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3	BLU-222 Sensitive: C3 – Early Trials BLU-222 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D	ribociclib + BLU-222 Sensitive: D – Preclinical ribociclib + BLU-222 Sensitive : D
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D	palbociclib + BLU-222 Sensitive: D – Preclinical palbociclib + BLU-222 Sensitive : D